Drugs / ABP 710
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02937701 | Oct 2016 → Apr 2018 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-12-17 | Amgen | Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration amgen.com ↗ |
| 2018-06-27 | Amgen | Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab amgen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABP 710 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02937701 ↗ |
| Route | Intravenous | “Administered by intravenous infusion” NCT02937701 ↗ |